Speaker Profile
Ph.D., CEO and CSO, Phinomics
Biography
Massa Shoura is the CEO and CSO of Phinomics, an innovative company transforming precision medicine by unlocking the potential of circular DNA and integrating genomics with advanced AI. With dual PhDs in Molecular Biology and Biomedical Engineering, Massa has over a decade of expertise in DNA topology, biophysics, and genomics. During her postdoctoral fellowship at Stanford University in Nobel Laureate Dr. Andrew Fires lab, she developed groundbreaking tools for isolating and characterizing circular DNA, earning prestigious fellowships, including the Arnold O. Beckman Fellowship, and securing two granted patents. As a Forbeck Scholar, she advanced cancer genomics by uncovering the role of oncogenic circular DNA amplification. She also spearheaded the sequencing and publication of Pfizer and Moderna COVID-19 vaccine mRNAs, showcasing her commitment to global health. At Phinomics, Massa leads the development of first-in-class precision oncology solutions through the Circulome Atlas, a transformative platform providing unparalleled insights into cancer etiology, progression, and therapeutic resistance.
Talk
Leveraging Circulome Data and AI for Precision Oncology
Discover how Phinomics leverages the power of circular DNA and the Circulome Atlas, using advanced AI approaches to mine this unique resource for first-in-class biomarkers and therapeutic targets. Learn how our platform accelerates discovery, empowers precision oncology, and drives the future of personalized medicine with transformative insights into cancer biology.
AI and Data Sciences Showcase:
Phinomics
Phinomics is revolutionizing precision medicine by harnessing the power of circular DNA to uncover novel biomarkers, accelerate therapeutic discovery, and deliver unparalleled insights into cancer biology and other diseases.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
